Big Data: What Every Rheumatologist Should Know
To better understand big data, Healio Rheumatology spoke with leaders of the Corrona, ArthritisPower, BRASS, ImmPort and RISE registries and discussed what these registries provide for rheumatologists and the benefits of big data in general for rheumatology. Read More.
Experts Discuss the Quandary of Whether to Discontinue or Taper Treatment and When
For the last few decades, clinicians have been trying to figure out how to decrease therapy in patients with rheumatoid arthritis who have reached stable remission. Various strategies for tapering or discontinuing treatment altogether have been explored to inconclusive results. This is not to say tapering therapy has been unsuccessful or discontinuing absolutely leads to immediate or uncontrollable flare. Flares happen and re-initiation of treatment is often necessary. Therefore, the questions at hand pertain to timing, dosage levels, clinical decision-making, and the interplay between steroid and biologic therapies. Read More.
Through the Cracks: Niche Patient Population Battles Dermatopathologic Complications of Rheumatic Disease
Patients with serious skin complications associated with rheumatic diseases may face a host of obstacles. Misdiagnosis is common. They are treated with non-curative therapies that can carry complications. Where rheumatology ends and dermatology begins is often a blurry line, so patients find themselves volleying between specialties. Read More.
What Rheumatologists Need to Know About Janus Kinase Inhibitors
To better understand this drug class, Healio Rheumatology reviewed the latest clinical trials and spoke with experts about the mechanisms, safety and future potential of these options. Read More.
Fewer Steroids, Longer Remission: Staying Ahead of Vasculitis
The most recent American College of Rheumatology-endorsed criteria for the classification of vasculitis were published in 1990. At the American College of Rheumatology Annual Meeting last year, a novel set of criteria were rolled out in a comprehensive 90-minute session, but the document is under review and will not be presented until the 2017 annual meeting. Read More.